Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.

about

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.

Item

http://www.wikidata.org/entity/Q49449891

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Paricalcitol Versus Calcifedio ...... Kidney Transplant Recipients.

@en

Paricalcitol Versus Calcifedio ...... Kidney Transplant Recipients.

@nl

type

Item

label

Paricalcitol Versus Calcifedio ...... Kidney Transplant Recipients.

@en

Paricalcitol Versus Calcifedio ...... Kidney Transplant Recipients.

@nl

prefLabel

Paricalcitol Versus Calcifedio ...... Kidney Transplant Recipients.

@en

Paricalcitol Versus Calcifedio ...... Kidney Transplant Recipients.

@nl

P1476

Paricalcitol Versus Calcifedio ...... n Kidney Transplant Recipients

@en

P2093

Alex Gutierrez-Dalmau

http://www.w3.org/2001/XMLSchema#string

Amado Andrés

http://www.w3.org/2001/XMLSchema#string

Domingo Hernández

http://www.w3.org/2001/XMLSchema#string

Francesc Moreso

http://www.w3.org/2001/XMLSchema#string

Josep M Cruzado

http://www.w3.org/2001/XMLSchema#string

Julio Pascual

http://www.w3.org/2001/XMLSchema#string

Manuel Arias

http://www.w3.org/2001/XMLSchema#string

Manuel Praga

http://www.w3.org/2001/XMLSchema#string

Maria Isabel Beneyto

http://www.w3.org/2001/XMLSchema#string

Ricardo Lauzurica

http://www.w3.org/2001/XMLSchema#string

P2860

Calcium metabolism and skeletal problems after transplantation.

VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,0

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies.

Bone disease after renal transplantation.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure.

Decreased Kidney Graft Survival in Low Immunological Risk Patients Showing Inflammation in Normal Protocol Biopsies.

Clinical use of serum and urine bone markers in the management of osteoporosis.

P304

122-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EKIR.2017.08.016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Armando Torres

Edoardo Melilli

Anna Manonelles

P577

2017-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29340322

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism

P932

5762965

http://www.w3.org/2001/XMLSchema#string